News
WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s
AstraZeneca/Daiichi Sankyo and Gilead Sciences have reported preliminary results of studies that suggest their TROP2-targeted antibody-drug conjugates (ADCs) could have a
